Advertisement

Viral Vaccines in India: An Overview

  • Kaushik Bharati
  • Sudhanshu Vrati
Review

Abstract

Viruses cause a large number of diseases in humans, some of which are fatal, while others are highly debilitating. A majority of viral diseases attack infants and young children, while others strike people in their prime. Development of preventive measures against viral diseases is, therefore, of paramount importance. Vaccination is the most cost-effective medical intervention for preventing mortality and morbidity against infectious diseases. A number of effective and safe vaccines are currently available against several viral diseases of significant medical importance. Many of these manufactured in India, are at par with international standards and are affordable. For many other viral diseases, for which vaccines are currently not available, research is underway at various national laboratories, as well as in the private sector companies in India. The present overview highlights the various vaccine preventable viral diseases that are of special importance to India and aims to provide a glimpse of the various vaccines that are currently available, or are under development in India.

Keywords

Virus Vaccine Immunization India 

References

  1. 1.
    Madhavi Y (2005) Vaccine policy in India. PLoS Med 2:e127PubMedGoogle Scholar
  2. 2.
    Lohray BB (2003) Medical biotechnology in India. Adv Biochem Eng Biotechnol 85:215–281PubMedGoogle Scholar
  3. 3.
    Gogtay NJ, Dhingra MS, Yadav A, Chandwani H (2009) Vaccine policy, regulations and safety in India. Int J Risk Saf Med 21:23–30Google Scholar
  4. 4.
    Rand R (2010) Bethesda biotech focuses on personalized vaccines. BioWatch, June 25, 2010. http://www.gazette.net/stories/06252010/businew170825_32549.php. Accessed on 11 April 2011
  5. 5.
    Som N (2010) Serum Institute launches intra-nasal swine flu vaccine Nasovac in India. BioSpectrum (Asia Edition) July 15, 2010. http://www.biospectrumasia.com/content/150710IND13091.asp. Accessed on 14 April 2011
  6. 6.
    CyberMedia (2010) Bangalore loses India’s top biotech city tag. CyberMedia News June 17, 2010. http://www.ciol.com. Accessed 11 April 2011
  7. 7.
    Suresh N, Rao CS (2009) Profiles of four top biotech companies in India. Biotechnol J 4:295–300PubMedGoogle Scholar
  8. 8.
    UPA Government (2010) Report to the people 2009–2010 (presented by Prime Minister Manmohan Singh to mark the completion of the first year of the UPA Government’s second five-year term), May 7, 2010: http://pmindia.nic.in/english_report_01.06.10.pdf. Accessed on 14 April 2011
  9. 9.
    Morens DM, Folkers GK, Fauci AS (2004) The challenge of emerging and re-emerging infectious diseases. Nature 430:242–249PubMedGoogle Scholar
  10. 10.
    Bharati K, Vrati S (2009) Japanese encephalitis. In: Sharma SK, Singal RK, Agarwal AK (eds) Monograph on adult immunization the association of physicians of India. Jaypee Brothers Medical Publishers (P) Ltd., New Delhi, pp 104–110Google Scholar
  11. 11.
    Senior K (2008) Is Japanese encephalitis control achievable by 2013? Lancet Infect Dis 8:534Google Scholar
  12. 12.
    Carey DE, Myers RM, Pavri KM (1968) Japanese encephalitis studies in Vellore, South India. II. Antibody response of patients. Indian J Med Res 56:1319–1329PubMedGoogle Scholar
  13. 13.
    Chakravarty SK, Sarkar JK, Chakravarty MS, Mukherjee MK, Mukherjee KK, Das BC, Hati AK (1975) The first epidemic of Japanese encephalitis studied in India—virological studies. Indian J Med Res 63:77–82PubMedGoogle Scholar
  14. 14.
    Rajalakshmi TK (2008) Testing times. Frontline 25(7) March 29–April 11, 2008. http://www.hindu.com/fline/fl2507/stories/20080411250702500.htm. Accessed 8 May 2011
  15. 15.
    Halstead SB, Thomas SJ (2010) New vaccines for Japanese encephalitis. Curr Infect Dis Rep 12:174–180PubMedGoogle Scholar
  16. 16.
    Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, Schuller E, Klade CS (2011) Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO®, IC51. Vaccine 29:2607–2612PubMedGoogle Scholar
  17. 17.
    Appaiahgari MB, Vrati S (2010) IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vaccines 9:1371–1384PubMedGoogle Scholar
  18. 18.
    Appaiahgari MB, Vrati S (2004) Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine 22:3669–3675PubMedGoogle Scholar
  19. 19.
    Bharati K, Rani R, Vrati S (2009) Evaluation of Japanese encephalitis virus DNA vaccine candidates in rhesus monkeys [Macaca mulatta]. Vaccine 27:10–16PubMedGoogle Scholar
  20. 20.
    Appaiahgari MB, Saini M, Rauthan M, Jyoti, Vrati S (2006) Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microb Infect 8:92–104Google Scholar
  21. 21.
    Robb ML (2008) Failure of Merck HIV vaccine: an uncertain step forward. Lancet 372:1857–1858PubMedGoogle Scholar
  22. 22.
    Halstead SB (2007) Dengue. Lancet 370:1644–1652PubMedGoogle Scholar
  23. 23.
    Mathew A, Rothman AL (2008) Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol Rev 225:300–313PubMedGoogle Scholar
  24. 24.
    Halstead SB (2003) Neutralization and antibody dependent enhancement of dengue viruses. Adv Virus Res 60:421–467PubMedGoogle Scholar
  25. 25.
    Gubler DJ, Meltzer M (1999) Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Res 53:35–70PubMedGoogle Scholar
  26. 26.
    Lee IK, Lee WH, Yang KD, Liu JW (2010) Comparison of the effects of oral hydration and intravenous fluid replacement in adult patients with non-shock dengue hemorrhagic fever in Taiwan. Trans R Soc Trop Med Hyg 104:541–545PubMedGoogle Scholar
  27. 27.
    Julander JG, Perry ST, Shresta S (2011) Important advances in the field of anti-dengue virus research. Antivir Chem Chemother 21:105–116PubMedGoogle Scholar
  28. 28.
    Khanam S, Pilankatta R, Khanna N, Swaminathan S (2009) An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 27:6011–6021PubMedGoogle Scholar
  29. 29.
    Gubler DJ, Roehrig JT (1998) Arboviruses (Togaviridae and Flaviviridae) (Chapter 29) In: Collier L, Balows A, Sussman M (eds) vo 1: Mahy BWJ, Collier L (eds) Virology: topley & wilson’s microbiology and microbial infections, 9th edn. Arnold, a Member of the Hodder Headline Group, London, Sydney, Auckland, 579–600Google Scholar
  30. 30.
    Mavalankar D, Shastri P, Raman P (2007) Chikungunya epidemic in India: a major public-health disaster. Lancet Infect Dis 7:306–307PubMedGoogle Scholar
  31. 31.
    Tandale BV, Santhe PS, Arankalle VA, Wadia RS, Kulkarni R, Shah SV, Shah SK, Sheth JK, Sudeep AB, Tripathy AS, Mishra AC (2009) Systemic involvements and fatalities during Chikungunya epidemic in India, 2006. J Clin Virol 46:145–149PubMedGoogle Scholar
  32. 32.
    Tiwari M, Parida M, Santosh SR, Khan M, Dash PK, Rao PVL (2009) Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27:2513–2522PubMedGoogle Scholar
  33. 33.
    Basak S, Mondal A, Polley S, Mukhopadhyay S, Chattopadhyay D (2007) Reviewing Chandipura: A vesiculovirus in human epidemics. Biosci Rep 27:275–298PubMedGoogle Scholar
  34. 34.
    Bhatt PN, Rodrigues FM (1967) Chandipura virus: A new arbovirus isolated in India from patients with febrile illness. Indian J Med Res 55:1295–1305PubMedGoogle Scholar
  35. 35.
    Rodrigues JJ, Singh PB, Dave DS, Prasan R, Ayachit V, Shaikh BH, Pavri KM (1983) Isolation of Chandipura virus from the blood in acute encephalopathy syndrome. Indian J Med Res 77:303–307PubMedGoogle Scholar
  36. 36.
    Rao BL, Basu A, Wairagkar NS, Gore MM, Arankalle VA, Thakare JP, Jadi RS, Rao KA, Mishra AC (2004) A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus. Lancet 364:869–874PubMedGoogle Scholar
  37. 37.
    Chadha MS, Arankalle VA, Jadi RS, Joshi MV, Thakare JP, Mahadev PVM, Mishra AC (2005) An outbreak of Chandipura virus encephalitis in the eastern districts of Gujarat state, India. Am J Trop Med Hyg 73:566–570PubMedGoogle Scholar
  38. 38.
    Gurav YK, Tandale BV, Jadi RS, Gunjikar RS, Tikute SS, Jamgaonkar AV, Khadse RK, Jalgaonkar SV, Arankalle VA, Mishra AC (2010) Chandipura virus encephalitis outbreak among children in Nagpur division, Maharashtra, 2007. Indian J Med Res 132:395–399PubMedGoogle Scholar
  39. 39.
    Dhanda V, Rodrigues FM, Ghosh SN (1970) Isolation of Chandipura virus from sand flies in Aurangabad. Indian J Med Res 58:179–180PubMedGoogle Scholar
  40. 40.
    Geevarghese G, Arankalle VA, Jadi R, Kanojia PC, Joshi MV, Mishra AC (2005) Detection of Chandipura virus from sand flies in the genus Sergentomyia (Diptera: Phlebotomidae) at Karimnagar District, Andhra Pradesh, India. J Med Entomol 42:495–496PubMedGoogle Scholar
  41. 41.
    Mavale MS, Fulmali PV, Ghodke YS, Mishra AC, Kanojia P, Geevarghese G (2007) Experimental transmission of Chandipura virus by Phlebotomus argentipes (Diptera: Psychodidae). Am J Trop Med Hyg 76:307–309PubMedGoogle Scholar
  42. 42.
    Venkateswarlu CH, Arankalle VA (2009) Recombinant glycoprotein based vaccine for Chandipura virus infection. Vaccine 27:2845–2850PubMedGoogle Scholar
  43. 43.
    Million Death Study Collaborators, Bassani DG, Kumar R, Awasthi S, Morris SK, Paul VK, Shet A, Ram U, Gaffey MF, Black RE, Jha P (2010) Causes of neonatal and child mortality in India: a nationally representative mortality survey. Lancet 376:1853–1860PubMedGoogle Scholar
  44. 44.
    Tate JE, Chitambar S, Esposito DH, Sarkar R, Gladstone B, Ramani S, Raghava MV, Sowmyanarayanan TV, Gandhe S, Arora R, Parashar UD, Kang G (2009) Disease and economic burden of rotavirus diarrhoea in India. Vaccine 275:F18–F24Google Scholar
  45. 45.
    Estes MK, Kapikian AZ (2007) Rotaviruses. In: Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B, Straus SE (eds) Fields virology, 5th edn. Lippincott-Raven, Philadelphia, pp 1917–1974Google Scholar
  46. 46.
    Solberg OD, Hasing ME, Trueba G, Eisenberg JNS (2009) Characterization of novel VP7, VP4, and VP6 genotypes of a previously untypeable group A rotavirus. Virology 385:58–67PubMedGoogle Scholar
  47. 47.
    Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, Jain V, Cunliffe NA, Nakagomi O, Kirkwood CD, Fischer TK, Parashar UD, Bresee JS, Jiang B, Glass RI (2005) Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 192:S146–S159PubMedGoogle Scholar
  48. 48.
    Santos N, Hoshino Y (2005) Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 15:29–56PubMedGoogle Scholar
  49. 49.
    Rose J, Hawthorn RL, Watts B, Singer ME (2009) Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. Br Med J 339:b3653Google Scholar
  50. 50.
    Esposito DH, Tate JE, Kang G, Parashar UD (2011) Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008. Clin Infect Dis 52:171–177PubMedGoogle Scholar
  51. 51.
    Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen-Chandolia T, Appaiahgari MB, Mishra A, Singh S, Vrati S, Rotavirus Vaccine Development Group (2009) A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J Infect Dis 200:421–429PubMedGoogle Scholar
  52. 52.
    Clements-Mann ML, Makhene MK, Mrukowicz J, Wright PF, Hoshino Y, Midthun K, Sperber E, Karron R, Kapikian AZ (1999) Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine 17:2715–2725PubMedGoogle Scholar
  53. 53.
    Clements-Mann ML, Dudas R, Hoshino Y, Nehring P, Sperber E, Wagner M, Stephens I, Karron R, Deforest A, Kapikian AZ (2001) Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine 19:4676–4684PubMedGoogle Scholar
  54. 54.
    Menezes R (2008) Rabies in India. Can Med Assoc J 178:564–566Google Scholar
  55. 55.
    World Health Organization (2010) Rabies vaccines: WHO position paper. Wkly Epidemiol Rec 85:309–320Google Scholar
  56. 56.
    Gadre G, Satishchandra P, Mahadevan A, Suja MS, Madhusudana SN, Sundaram C, Shankar SK (2010) Rabies viral encephalitis: clinical determinants in diagnosis with special reference to paralytic form. J Neurol Neurosurg Psychiatry 81:812–820PubMedGoogle Scholar
  57. 57.
    Finke S, Conzelmann KK (2005) Replication strategies of rabies virus. Virus Res 111:120–131PubMedGoogle Scholar
  58. 58.
    World Health Organization (2005) WHO expert consultation on rabies: first report. WHO Tech Rep Ser No. 931. World Health Organization, GenevaGoogle Scholar
  59. 59.
    Sampath G, Madhusudana SN, Sudarshan MK, Ashwathnarayana DH, Mahendra BJ, Ullas TP, Mohan K, Madhusudhan SK, Ravish HS (2010) Immunogenicity and safety of Indirab: a Vero cell based chromatographically purified human rabies vaccine. Vaccine 28:4086–4090PubMedGoogle Scholar
  60. 60.
    Sudarshan MK, Bhardwaj S, Mahendra BJ, Sharma H, Sanjay TV, Ashwathnarayana DH, Bilagumba G (2008) An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax®) in Indian subjects. Hum Vaccin 4:275–279PubMedGoogle Scholar
  61. 61.
    Ashwathnarayana DH, Madhusudana SN, Sampath G, Sathpathy DM, Mankeshwar R, Ravish HHS, Ullas PT, Behra TR, Sudarshan MK, Gangaboraiah, Shamanna M (2010) A comparative study on the safety and immunogenicity of purified duck embryo vaccine (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purified vero cell rabies vaccine (PVRV, Verorab). Vaccine 28:148–151Google Scholar
  62. 62.
    Mahendra BJ, Madhusudana SN, Sampath G, Datta SS, Ashwathnarayana DH, Venkatesh GM, Sudarshan MK, Bilugumba G, Shamanna M (2010) Immunogenicity, safety and tolerance of a purified duck embryo vaccine (PDEV, VAXIRAB) for rabies post-exposure prophylaxis: results of a multicentric study in India. Hum Vaccin 6:721–724Google Scholar
  63. 63.
    Rahim A, Kuppuswamy K, Thomas B, Raphael L (2010) Intradermal cell culture rabies vaccine: a cost effective option in antirabies treatment. Indian J Community Med 35:443–444PubMedGoogle Scholar
  64. 64.
    Gupta PK, Dahiya SS, Kumar P, Rai A, Patel CL, Sonwane AA, Saini M (2009) Sindbis virus replicon-based DNA vaccine candidate encoding rabies virus glycoprotein elicits specific humoral and cellular immune response in dogs. Acta Virol 53:83–88PubMedGoogle Scholar
  65. 65.
    Kaur M, Saxena A, Rai A, Bhatnagar R (2010) Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice. FASEB J 24:173–183PubMedGoogle Scholar
  66. 66.
    Ramya R, Verma PC, Chaturvedi VK, Gupta PK, Pandey KD, Madhanmohan M, Kannaki TR, Sridevi R, Anukumar B (2009) Poly (lactide-co-glycolide) microspheres: a potent oral delivery system to elicit systemic immune response against inactivated rabies virus. Vaccine 27:2138–2143PubMedGoogle Scholar
  67. 67.
    World Health Organization (2011) Hepatitis B: introducing hepatitis b vaccine in Universal Immunization Programme in India—a brief scenario. WHO India, 2011. http://www.whoindia.org/en/section6%5Csection8.htm. Accessed 18 April 2011
  68. 68.
    World Health Organization (2009) Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec 84:405–420Google Scholar
  69. 69.
    Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, Chen CL (1983) Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 2:1099–1102PubMedGoogle Scholar
  70. 70.
    Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, Ma HK (1984) Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet 1:921–926PubMedGoogle Scholar
  71. 71.
    Bavdekar SB, Maiya PP, Subba Rao SD, Datta SK, Bock HL (2007) Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/Haemophilus influenzae type b vaccine in Indian infants. Indian Pediatr 44:505–510PubMedGoogle Scholar
  72. 72.
    Pichichero ME, Bernstein H, Blatter MM, Schuerman L, Cheuvart B, Holmes SJ, 085 Study Investigators (2007) Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine. J Pediatr 151:43–49PubMedGoogle Scholar
  73. 73.
    Heininger U, DTP-HBV-IPV-059 Study Group, DTP-HBV-IPV-096 Study Group, Sänger R, Jacquet JM, Schuerman L (2007) Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 25:1055–1063PubMedGoogle Scholar
  74. 74.
    Shah KV, Howley PM (1990) Papillomavirus. In: Fields BN, Knipe DM, Chanock RM, Hirsch MS, Melnik TP, Roizman B (eds) Fields virology, 2nd edn. Raven Press Ltd., New York, pp 1651–1676Google Scholar
  75. 75.
    Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87:796–802PubMedGoogle Scholar
  76. 76.
    Koutsky LA, Galloway DA, Holmes KK (1997) Epidemiology of genital human papillomavirus infection. Am J Med 102:3–8PubMedGoogle Scholar
  77. 77.
    Ho GYF, Bierma R, Beardsley L, Chan CJ, Burk RD (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423–428PubMedGoogle Scholar
  78. 78.
    Parkin DM, Bray F, Ferlay J, Pisani P (2004) GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC cancer base No. 5, version 2.0. IARC Press, LyonGoogle Scholar
  79. 79.
    Indian Academy of Pediatrics Committee on Immunization (IAPCOI) (2008) Consensus recommendations on immunization, 2008. Indian Pediatr 45:635–648Google Scholar
  80. 80.
    CDC Vaccine Price List (2011) http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm. Accessed 19 April 2011
  81. 81.
    Gacic-Dobo M, Mayers G, Birmingham M, Kane M, Hadler SC, Perilla MJ, Shaw FE, Goldstein ST, Mast EE, Margolis HS, Samandari T (2003) Global progress toward universal childhood hepatitis B vaccination, 2003. Morb Mortal Wkly Rep 52:868–870Google Scholar
  82. 82.
    Padmanabhan S, Amin T, Sampat B, Cook-Deegan R, Chandrasekharan S (2010) Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. Nat Biotechnol 28:671–678PubMedGoogle Scholar
  83. 83.
    Sinha GP (2007) Shantha developing $15 cervical cancer vaccine. The Economic Times October 16, 2007. http://articles.economictimes.indiatimes.com/2007-10-16/news/27671464_1_cervical-cancer-vaccine-merck-s-gardasil-hpv-types. Accessed 19 April 2011
  84. 84.
    Biotechnology Industry Partnership Programme (BIPP), Department of Biotechnology, Government of India (2011) Products/processes under development through BIPP support. http://www.birapdbt.nic.in/uploads/Upload_Dec2010/Products-Processes_Under_Development_Through_BIPP_Support.pdf. Accessed 19 April 2011
  85. 85.
    Oxman MN (1997) Measles. In: Richman DD, Whitley RJ, Hayden FG (eds) Clinical virology, 1st edn. Churchill Livingstone, New York, pp 821–861Google Scholar
  86. 86.
    Dabbagh A, Gacic-Dobo M, Simons E, Featherstone D, Strebel P, Okwo-Bele JM, Hoekstra E, Chopra M, Uzicanin A, Cochi S (2009) Global measles mortality, 2000–2008. Morb Mortal Wkly Rep 58:1321–1326Google Scholar
  87. 87.
    van den Ent M, Gupta SK, Hoekstra E (2009) Two doses of measles vaccine reduce measles deaths. Indian Pediatr 46:933–938PubMedGoogle Scholar
  88. 88.
    World Health Organization (2009) Meeting of the immunization Strategic Advisory Group of Experts, November 2008—conclusions and recommendations. Wkly Epidemiol Rec 84:1–16Google Scholar
  89. 89.
    Amdekar YK, Singhal T (2008) Measles vaccine deaths—the IAP-COI stand. Indian Pediatr 45:479–480PubMedGoogle Scholar
  90. 90.
    Geddes AM, Bryceson ADM, Thin RN, Mitchell DM (1995) Diseases due to infection. In: Edwards CRW, Bouchier IAD, Haslett C, Chilvers ER (eds) Davidson’s principles and practice of medicine, 17th edn. ELBS with Churchill Livingstone, Edinburgh, pp 65–189Google Scholar
  91. 91.
    Yadav S, Thukral R, Chakarvarti A (2003) Comparative evaluation of measles, mumps and rubella vaccine at 9 and 15 months of age. Indian J Med Res 118:183–186PubMedGoogle Scholar
  92. 92.
    Raut SK, Kulkarni PS, Phadke MA, Jadav SS, Kapre SV, Dhere RM, Dhorje SP, Godse SR (2007) Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India. Clin Vaccine Immunol 14:1370–1371PubMedGoogle Scholar
  93. 93.
    Indian Academy of Pediatrics (2011) Immunization schedule: January–March 2011. http://www.iapindia.org/immunisation/immunisation-schedule. Accessed 20 April 2011
  94. 94.
    John TJ (2004) An outbreak of mumps in Thiruvananthapuram district. Indian Pediatr 41:298–300PubMedGoogle Scholar
  95. 95.
    Abraham M, Abraham P, Jana AK, Kuruvilla KA, Cherian T, Moses PD, Mathai E, John TJ, Sridharan G (1999) Serology in congenital infections: experience in selected symptomatic infants. Indian Pediatr 36:697–700PubMedGoogle Scholar
  96. 96.
    Gupta E, Dar L, Broor S (2006) Seroprevalence of rubella in pregnant women in Delhi, India. Indian J Med Res 123:833–835PubMedGoogle Scholar
  97. 97.
    Advisory Committee on Immunization Practices (2007) Recommended adult immunization: United States, October 2007–September 2008. Ann Intern Med 147:725–729Google Scholar
  98. 98.
    Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C (2002) Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2:25–32PubMedGoogle Scholar
  99. 99.
    Reddaiah VP, Kapoor SK (1988) Acute respiratory infections in rural under fives. Indian J Pediatr 55:424–426PubMedGoogle Scholar
  100. 100.
    Cox NJ, Subbarao K (1999) Influenza. Lancet 354:1277–1282PubMedGoogle Scholar
  101. 101.
    Hayden FG, Palese P (1997) Influenza virus. In: Richman DD, Whitley RJ, Hayden FG (eds) Clinical virology, 1st edn. Churchill Livingstone, New York, pp 911–942Google Scholar
  102. 102.
    Broor S, Parveen S, Bharaj P, Prasad VS, Srinivasulu KN, Sumanth KM, Kapoor SK, Fowler K, Sullender WM (2007) A prospective three-year cohort study of the epidemiology and virology of acute respiratory infections of children in rural India. PLoS ONE 2:e491PubMedGoogle Scholar
  103. 103.
    Ramamurthy N, Pillai LC, Gunasekaran P, Elango V, Mohana, Priya P, Sheriff AK (2005) Influenza activity among the pediatric age group in Chennai. Indian J Med Res 121:776–779Google Scholar
  104. 104.
    Mathew JL (2009) Influenza vaccination for children in India. Indian Pediatr 46:304–307PubMedGoogle Scholar
  105. 105.
    Balkhy HH, Memish ZA, Bafaqeer S, Almuneef MA (2004) Influenza a common viral infection among Hajj pilgrims: time for routine surveillance and vaccination. J Travel Med 11:82–86PubMedGoogle Scholar
  106. 106.
    Jameel S (2010) The 2009 influenza pandemic. Curr Sci 98:306–311Google Scholar
  107. 107.
    Ray K, Potdar VA, Cherian SS, Pawar SD, Jadhav SM, Waregaonkar SR, Joshi AA, Mishra AC (2008) Characterization of the complete genome of influenza A (H5N1) virus isolated during the 2006 outbreak in poultry in India. Virus Genes 36:345–353PubMedGoogle Scholar
  108. 108.
    Bharat Biotech (2009) Product pipeline. http://www.bharatbiotech.com/prod_pipeline.htm. Accessed 22 April 2011
  109. 109.
    Rotbart HA (1997) Enteroviruses. In: Richman DD, Whitley RJ, Hayden FG (eds) Clinical virology, 1st edn. Churchill Livingstone, New York, pp 997–1023Google Scholar
  110. 110.
    Global Polio Eradication Initiative. Infected countries: http://www.polioeradication.org/Infectedcountries.aspx. Accessed 23 April 2011
  111. 111.
    Sutter RW, John TJ, Jain H, Agarkhedkar S, Ramanan PV, Verma H, Deshpande J, Singh AP, Sreevatsava M, Malankar P, Burton A, Chatterjee A, Jafari H, Aylward RB (2010) Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomized, double-blind, controlled trial. Lancet 376:1682–1688PubMedGoogle Scholar
  112. 112.
    Global Polio Eradication Initiative (2011) Data and monitoring—polio this week. http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx. Accessed 23 April 2011
  113. 113.
    World Health Organization (2011) WHO prequalified vaccines: http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html. Accessed 23 April 2011
  114. 114.
    Folks TM, Khabbaz RF (1998) Retroviruses and associated diseases in humans (Chapter 38) In: Collier L, Balows A, Sussman M (eds) vol 1: Mahy BWJ, Collier L (eds) Virology: topley & wilson’s microbiology and microbial infections, 9th edn. Arnold, a Member of the Hodder Headline Group, London, Sydney, Auckland, pp 781–803Google Scholar
  115. 115.
    The rgp120 HIV Vaccine Study Group (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191:654–665Google Scholar
  116. 116.
    Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K (2006) Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194:1661–1671PubMedGoogle Scholar
  117. 117.
    Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Pemsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, for the MOPH-TAVEG Investigators (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220PubMedGoogle Scholar
  118. 118.
    International AIDS Vaccine Initiative (IAVI) (2011) Research and Development: clinical trials. http://www.iavi.org/researchdevelopment/trials/Pages/ClinicalTrials.aspx. Accessed 24 April 2011
  119. 119.
    Stover J, Bollinger L, Hecht R, Williams C, Roca E (2007) The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff 26:1147–1158Google Scholar

Copyright information

© The National Academy of Sciences, India 2012

Authors and Affiliations

  1. 1.Vaccine and Infectious Disease Research CentreTranslational Health Science and Technology InstituteGurgaonIndia
  2. 2.National Institute of ImmunologyNew DelhiIndia

Personalised recommendations